SK80697A3 - Use of mhc-ii binding molecules - Google Patents

Use of mhc-ii binding molecules Download PDF

Info

Publication number: SK80697A3
Authority: SK; Slovakia
Prior art keywords: mhc; molecules; lps; cell; diseases
Prior art date: 1994-12-23

Application number

SK806-97A

Other languages

English (en)

Slovak (sk)

Inventor

Roger P Lauener

Original Assignee

Om Lab Sa

Deutsche Om Arzneimittel Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-23

Filing date

1995-12-27

Publication date

1997-12-10

1995-12-27 Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa

1997-12-10 Publication of SK80697A3 publication Critical patent/SK80697A3/sk

Links

230000027455 binding Effects 0.000 title claims abstract description 28
210000004027 cell Anatomy 0.000 claims abstract description 76
239000002158 endotoxin Substances 0.000 claims abstract description 76
229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 76
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 69
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 69
102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract description 46
108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract description 18
230000003993 interaction Effects 0.000 claims abstract description 14
210000001539 phagocyte Anatomy 0.000 claims abstract description 9
241000192125 Firmicutes Species 0.000 claims abstract description 4
239000012634 fragment Substances 0.000 claims abstract description 4
201000010099 disease Diseases 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
206010061218 Inflammation Diseases 0.000 claims description 11
230000004054 inflammatory process Effects 0.000 claims description 11
210000000056 organ Anatomy 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 6
206010040070 Septic Shock Diseases 0.000 claims description 5
230000003213 activating effect Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
230000019491 signal transduction Effects 0.000 claims description 5
241000894006 Bacteria Species 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
206010025135 lupus erythematosus Diseases 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 3
230000007246 mechanism Effects 0.000 claims description 3
201000008383 nephritis Diseases 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims description 2
208000020119 Caplan syndrome Diseases 0.000 claims description 2
201000009030 Carcinoma Diseases 0.000 claims description 2
206010009900 Colitis ulcerative Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010016228 Fasciitis Diseases 0.000 claims description 2
208000028387 Felty syndrome Diseases 0.000 claims description 2
206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 2
206010018364 Glomerulonephritis Diseases 0.000 claims description 2
206010020850 Hyperthyroidism Diseases 0.000 claims description 2
208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
208000000112 Myalgia Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
206010039710 Scleroderma Diseases 0.000 claims description 2
208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
230000001363 autoimmune Effects 0.000 claims description 2
210000000601 blood cell Anatomy 0.000 claims description 2
238000010322 bone marrow transplantation Methods 0.000 claims description 2
201000001981 dermatomyositis Diseases 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
230000002327 eosinophilic effect Effects 0.000 claims description 2
206010016629 fibroma Diseases 0.000 claims description 2
201000008298 histiocytosis Diseases 0.000 claims description 2
208000003532 hypothyroidism Diseases 0.000 claims description 2
230000002989 hypothyroidism Effects 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
230000000771 oncological effect Effects 0.000 claims description 2
208000005987 polymyositis Diseases 0.000 claims description 2
230000000552 rheumatic effect Effects 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
208000024827 Alzheimer disease Diseases 0.000 claims 1
206010003210 Arteriosclerosis Diseases 0.000 claims 1
208000009329 Graft vs Host Disease Diseases 0.000 claims 1
208000011775 arteriosclerosis disease Diseases 0.000 claims 1
239000008187 granular material Substances 0.000 claims 1
230000035699 permeability Effects 0.000 claims 1
230000002123 temporal effect Effects 0.000 claims 1
238000002054 transplantation Methods 0.000 claims 1
230000004913 activation Effects 0.000 abstract description 14
108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
230000002452 interceptive effect Effects 0.000 abstract 1
108091054438 MHC class II family Proteins 0.000 description 47
238000002474 experimental method Methods 0.000 description 21
102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 19
108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 19
102000043131 MHC class II family Human genes 0.000 description 18
241000699670 Mus sp. Species 0.000 description 14
108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
238000001114 immunoprecipitation Methods 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
238000000034 method Methods 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000006228 supernatant Substances 0.000 description 9
108700002010 MHC class II transactivator Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
230000028327 secretion Effects 0.000 description 8
102000006354 HLA-DR Antigens Human genes 0.000 description 7
108010058597 HLA-DR Antigens Proteins 0.000 description 7
101100382122 Homo sapiens CIITA gene Proteins 0.000 description 7
102100026371 MHC class II transactivator Human genes 0.000 description 7
239000008188 pellet Substances 0.000 description 7
229920000936 Agarose Polymers 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
230000020411 cell activation Effects 0.000 description 6
238000000975 co-precipitation Methods 0.000 description 6
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000006166 lysate Substances 0.000 description 6
210000001616 monocyte Anatomy 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
108010002352 Interleukin-1 Proteins 0.000 description 5
102000000589 Interleukin-1 Human genes 0.000 description 5
108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 5
102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000002285 radioactive effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
238000013519 translation Methods 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102000004890 Interleukin-8 Human genes 0.000 description 4
108090001007 Interleukin-8 Proteins 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
229940009976 deoxycholate Drugs 0.000 description 4
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
238000002372 labelling Methods 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
238000001890 transfection Methods 0.000 description 4
239000011534 wash buffer Substances 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
231100000776 exotoxin Toxicity 0.000 description 3
239000002095 exotoxin Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000032258 transport Effects 0.000 description 3
BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
102100025390 Integrin beta-2 Human genes 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000010399 physical interaction Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
241001135569 Human adenovirus 5 Species 0.000 description 1
208000034174 Immunodeficiency by defective expression of MHC class II Diseases 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
206010023424 Kidney infection Diseases 0.000 description 1
201000009635 MHC class II deficiency Diseases 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
101710084578 Short neurotoxin 1 Proteins 0.000 description 1
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
101710182223 Toxin B Proteins 0.000 description 1
101710182532 Toxin a Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000003317 immunochromatography Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biophysics (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Virology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

SK806-97A 1994-12-23 1995-12-27 Use of mhc-ii binding molecules SK80697A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94203755		1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en)	1994-12-23	1995-12-27	Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number	Publication Date
SK80697A3 true SK80697A3 (en)	1997-12-10

Family

ID=8217495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK806-97A SK80697A3 (en)	1994-12-23	1995-12-27	Use of mhc-ii binding molecules

Country Status (11)

Country	Link
EP (1)	EP0800534A2 (pt)
JP (1)	JPH10511652A (pt)
CN (1)	CN1171117A (pt)
AU (1)	AU4347696A (pt)
BR (1)	BR9510554A (pt)
CA (1)	CA2208233A1 (pt)
CZ (1)	CZ186897A3 (pt)
HU (1)	HUT77468A (pt)
PL (1)	PL320922A1 (pt)
SK (1)	SK80697A3 (pt)
WO (1)	WO1996020215A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5840835A (en) *	1995-10-30	1998-11-24	Merck & Co., Inc.	Inhibitors of peptide binding to MHC class II proteins
US5719296A (en) *	1995-10-30	1998-02-17	Merck & Co., Inc.	Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) *	1995-10-30	1998-10-06	Merck & Co., Inc.	Inhibitors of peptide binding to MHO class II proteins
US6458354B1 (en)	1996-03-28	2002-10-01	The Johns Hopkins University	Molecular complexes which modify immune responses
CA2250166A1 (en)	1996-03-28	1997-10-02	The Johns Hopkins University	Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en)	1997-09-11	2001-07-31	The Johns Hopkins University	Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en)	1997-07-25	1999-01-27	Institut Gustave Roussy	Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
DK1404367T3 (da) *	2001-07-02	2010-12-13	Aimsco Ltd	Anvendelse af polyklonalt anti-HIV gedeserum som et terapeutisk middel
GB0201896D0 (en) *	2002-01-28	2002-03-13	Ice Biolog Ltd	Treatment
CA2473754C (en) *	2002-01-28	2012-04-10	Aimsco Limited	Treatment of ms with goat serum
ES2232273B1 (es) *	2003-03-21	2006-07-16	Jose Manuel Fernandez-Real Lemos	Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
DK1628530T3 (da) *	2003-05-15	2012-07-23	Genentech Inc	Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3269354D1 (en) *	1981-06-25	1986-04-03	Univ Leland Stanford Junior	Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) *	1983-04-18	1983-05-25	Mach B F	Cotransformed mouse cells
EP0204522A3 (en) *	1985-05-30	1987-09-16	Genetic Systems Corporation	Monoclonal antibody panel for histocompatibility typing
JPS63275526A (ja) *	1987-05-03	1988-11-14	Hiroshi Okajima	Ｈｉｖウイルス中和抗体
FR2658197B1 (fr) *	1990-02-14	1992-05-22	Inst Nat Sante Rech Med	Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE4029227A1 (de) *	1990-09-14	1992-03-19	Imtox Gmbh	Arzneimittel enthaltend cd14
AU3220593A (en) *	1991-11-19	1993-06-15	Anergen, Inc.	Soluble mhc molecules and their uses
CA2133758A1 (en) *	1992-04-06	1993-10-14	Sanna M. Goyert	A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
CA2125871A1 (en) *	1992-10-15	1994-04-28	Keishi Miwa	Process for preparing major histocompatibility antigen class ii protein and materials in which the same is bound
US5820858A (en) *	1993-05-28	1998-10-13	The Scripps Research Institute	Methods and compositions for inhibiting CD14 mediated cell activation
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies

1995
- 1995-12-27 AU AU43476/96A patent/AU4347696A/en not_active Abandoned
- 1995-12-27 JP JP8520220A patent/JPH10511652A/ja active Pending
- 1995-12-27 EP EP95942207A patent/EP0800534A2/en not_active Withdrawn
- 1995-12-27 BR BR9510554A patent/BR9510554A/pt not_active Application Discontinuation
- 1995-12-27 SK SK806-97A patent/SK80697A3/sk unknown
- 1995-12-27 CN CN95196985A patent/CN1171117A/zh active Pending
- 1995-12-27 CZ CZ971868A patent/CZ186897A3/cs unknown
- 1995-12-27 HU HU9800269A patent/HUT77468A/hu unknown
- 1995-12-27 WO PCT/EP1995/005164 patent/WO1996020215A2/en not_active Ceased
- 1995-12-27 PL PL95320922A patent/PL320922A1/xx unknown
- 1995-12-27 CA CA002208233A patent/CA2208233A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JPH10511652A (ja)	1998-11-10
BR9510554A (pt)	1999-06-29
WO1996020215A3 (en)	1996-10-10
PL320922A1 (en)	1997-11-10
HUT77468A (hu)	1998-05-28
WO1996020215A2 (en)	1996-07-04
EP0800534A2 (en)	1997-10-15
CA2208233A1 (en)	1996-07-04
CZ186897A3 (cs)	1998-03-18
AU4347696A (en)	1996-07-19
CN1171117A (zh)	1998-01-21

Publication	Publication Date	Title
Sanyal et al.	2017	MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells
Suda et al.	1997	Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
Weinstein et al.	1993	Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14.
Asavapanumas et al.	2014	Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG
Romani et al.	2004	The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans
Janssen et al.	2000	Regulation of activation-induced cell death of mature T-lymphocyte populations
Coutelier et al.	1994	B lymphocyte and macrophage expression of carcinoembryonic antigen‐related adhesion molecules that serve as receptors for murine coronavirus
EP3630158B1 (en)	2022-07-13	Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
Kojima et al.	2002	Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity
SK80697A3 (en)	1997-12-10	Use of mhc-ii binding molecules
Allenbach et al.	2008	An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection
Aravindhan et al.	2017	Cell type-specific immunomodulation induced by helminthes: effect on metainflammation, insulin resistance and type-2 diabetes
Bánki et al.	2019	Antibody opsonization enhances MAIT cell responsiveness to bacteria via a TNF‐dependent mechanism
Kissner et al.	2011	Activation of MyD88 signaling upon staphylococcal enterotoxin binding to MHC class II molecules
CN113621077B (zh)	2023-01-31	一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
JP2025069165A (ja)	2025-04-30	耐性を誘導するための操作された細胞
CA3154771A1 (en)	2021-04-15	Compositions and methods for treating cytotoxic t cell resistant tumors
EP1367393A1 (en)	2003-12-03	Methods for using the CD 163 pathway for modulating an immune response
Palermo et al.	1997	Fcγ receptor‐dependent clearance is enhanced following lipopolysaccharide in vivo treatment
AU6316799A (en)	2000-03-30	Use of MCH-II binding and/or MHC-II mimicking molecules for the prevention and/or treatment of inflammatory diseases
JP2016069314A (ja)	2016-05-09	免疫抑制剤
US10588941B2 (en)	2020-03-17	Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection
Song	2021	Hu5F9 anti-CD47 antibody promotes macrophage phagocytosis of SIV-infected cells in various infection stages
Müller-Eberhard et al.	1986	Molecular mechanisms of cytotoxicity: comparison of complement and killer lymphocytes
Tweedle	2018	TNF Antagonism Stifles Host Response to Pulmonary Pathogen through Gut/lung Immunoregulatory Axis